CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FINANCING AGREEMENT dated as of January 17, 2024 among...Financing Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT by and among Eidos...Exclusive License Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of March 1st, 2024 (the “Execution Date”) by and among Eidos Therapeutics, Inc., having its principal place of business at 1800 Owens Street, Suite C-1200, San Francisco, California 94158 U.S.A. (“E-Therapeutics”), BridgeBio International GmbH having its principal place of business at Bahnhofplatz 1, 8001, Zurich, Switzerland (“BBI”), and BridgeBio Europe B.V., having its principal place of business at Weederstein 97, 1083 GG Amsterdam, The Netherlands (“BBE” and collectively with E-Therapeutics and BBI, “Eidos”), on the one hand, and Bayer Consumer Care AG, having its principal place of business at Peter Merian-Strasse 84, 4052 Basel, Switzerland (“Bayer”), on the other hand. Eidos and Bayer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in the Background below shall have the meanings ascribed to such terms in Article 1 or elsewhe
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FUNDING AGREEMENTFunding Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
This FUNDING AGREEMENT (this “Agreement”), dated as of January 17, 2024 (the “Effective Date”), is made and entered into by and among (i) LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY, a designated activity company limited by shares duly incorporated under the laws of Ireland (“LSI”) and CPPIB CREDIT EUROPE S.À R.L., a private limited liability company (société à responsabilité limitée) incorporated and organized under the Laws of the Grand Duchy of Luxembourg (“CPPIB”), as purchasers (each in such capacity, together with its permitted successors and assigns in such capacity, a “Purchaser” and collectively, the “Purchasers”), (ii) BRIDGEBIO PHARMA, INC., a Delaware corporation (“BridgeBio”) (iii) EIDOS THERAPEUTICS, INC., a Delaware corporation ( “Eidos”), (iv) BRIDGEBIO EUROPE B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under Dutch law, having its corporate seat (statutaire zetel) in Amsterdam, the Netherlands, with
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO FINANCING AGREEMENTFinancing Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO FINANCING AGREEMENT (this “Amendment”), dated as of February 12, 2024, is entered into by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto, and BLUE OWL CAPITAL CORPORATION, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).
ContractExclusive (Equity) Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential.
AMENDMENT No. 3 TO CONSULTING AGREEMENTConsulting Agreement • May 2nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT No. 3 TO CONSULTING AGREEMENT (“Amendment No. 3”) is effective as of March 4, 2024 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 3160 Porter Drive, Suite 250, Palo Alto, California 94304, and Frank McCormick (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
